NZ594950A - Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3 - Google Patents

Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3

Info

Publication number
NZ594950A
NZ594950A NZ594950A NZ59495010A NZ594950A NZ 594950 A NZ594950 A NZ 594950A NZ 594950 A NZ594950 A NZ 594950A NZ 59495010 A NZ59495010 A NZ 59495010A NZ 594950 A NZ594950 A NZ 594950A
Authority
NZ
New Zealand
Prior art keywords
epha3
myeloproliferative disorder
patient
cells
treatment
Prior art date
Application number
NZ594950A
Other languages
English (en)
Inventor
Christopher R Bebbington
Original Assignee
Kalobios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalobios Pharmaceuticals Inc filed Critical Kalobios Pharmaceuticals Inc
Publication of NZ594950A publication Critical patent/NZ594950A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ594950A 2009-03-06 2010-03-05 Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3 NZ594950A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15828509P 2009-03-06 2009-03-06
US16813009P 2009-04-09 2009-04-09
PCT/US2010/026413 WO2010102244A1 (en) 2009-03-06 2010-03-05 Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3

Publications (1)

Publication Number Publication Date
NZ594950A true NZ594950A (en) 2013-06-28

Family

ID=42370943

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ594950A NZ594950A (en) 2009-03-06 2010-03-05 Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3

Country Status (9)

Country Link
US (3) US8834870B2 (https=)
EP (1) EP2403879A1 (https=)
JP (2) JP5876728B2 (https=)
CN (1) CN102405237A (https=)
AU (1) AU2010221159B2 (https=)
CA (1) CA2753995A1 (https=)
EA (1) EA201101241A1 (https=)
NZ (1) NZ594950A (https=)
WO (1) WO2010102244A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
WO2009023184A2 (en) * 2007-08-10 2009-02-19 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
CA2777068C (en) 2009-10-14 2020-05-26 Humanigen, Inc. Antibodies to epha3
EP2517555A4 (en) 2009-12-25 2014-09-24 Chugai Pharmaceutical Co Ltd SEARCHING AND SCREENING METHOD FOR A TARGET MOLECULE OF A CANCER WITH A NON-MENTAL ANIMAL MODEL WITH A NO-CANCER LINE OF TRANSPLANTED LINE
JP6230789B2 (ja) 2010-10-06 2017-11-15 中外製薬株式会社 癌幹細胞集団及びその作製方法
GB201021623D0 (en) * 2010-12-21 2011-02-02 Isis Innovation Detection of acute myeloid leukaemia
US9109032B2 (en) 2011-08-12 2015-08-18 Kalobios Pharmaceuticals, Inc. Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow
EP2749641B1 (en) 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
EP2772268B8 (en) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
WO2015093949A2 (en) * 2013-12-17 2015-06-25 Aimm Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
WO2021068040A1 (en) * 2019-10-09 2021-04-15 The Council Of The Queensland Institute Of Medical Research Targeting epha3 and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5674691A (en) 1991-06-21 1997-10-07 Amrad Corporation Limited Method of screening for ligands to a receptor-type tyrosine kinase
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
NO175798C (no) 1992-07-22 1994-12-07 Sinvent As Fremgangsmåte og anordning til aktiv stöydemping i et lokalt område
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
WO2000060070A1 (en) 1999-04-01 2000-10-12 Innogenetics N.V. A polypeptide structure for use as a scaffold
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
EP1094110A1 (en) 1999-10-21 2001-04-25 Leadd B.V. Apoptosis inducing proteinaceous substance
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CN101613705A (zh) 2002-03-19 2009-12-30 国际植物研究所 在植物中优化聚糖生成
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
AU2003900541A0 (en) * 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
EP1761561B1 (en) 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
EP1778726A4 (en) 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
WO2006052409A2 (en) * 2004-10-23 2006-05-18 Case Western Reserve University Peptide and small molecule agonists of epha and their uses
PT2343380T (pt) 2004-11-16 2019-09-18 Humanigen Inc Permuta de cassetes da região variável de imunoglobulina
JP2009526520A (ja) 2006-01-17 2009-07-23 バイオレックス セラピュティックス インク 植物中でのｎ−グリカンのヒト化及び最適化のための組成物及び方法
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
PL3199180T3 (pl) * 2007-03-08 2022-08-08 Humanigen, Inc. Przeciwciała przeciwko epha3 do leczenia guzów litych

Also Published As

Publication number Publication date
CA2753995A1 (en) 2010-09-10
EP2403879A1 (en) 2012-01-11
JP2015231994A (ja) 2015-12-24
EA201101241A1 (ru) 2012-04-30
US20100226930A1 (en) 2010-09-09
US20170226227A1 (en) 2017-08-10
AU2010221159B2 (en) 2015-11-26
CN102405237A (zh) 2012-04-04
AU2010221159A1 (en) 2011-09-22
WO2010102244A1 (en) 2010-09-10
JP5876728B2 (ja) 2016-03-02
JP2012519707A (ja) 2012-08-30
US20140370010A1 (en) 2014-12-18
US8834870B2 (en) 2014-09-16

Similar Documents

Publication Publication Date Title
NZ594950A (en) Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
MY199017A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy
WO2009086072A3 (en) Therapy of rituximab-refractory rheumatoid arthritis patients
MY178654A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy
MY163057A (en) Means and methods for trating dlblcl
MX2010002406A (es) Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii.
NZ716473A (en) Diagnosis and therapy of cancer involving cancer stem cells
MY191040A (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
GB2467467B (en) TAZ/WWTR1 for diagnosis and treatment of cancer
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
TW200637574A (en) Treatment method
WO2007089945A3 (en) Treating diseases by targeting silt3
MX2010005718A (es) Metodo para incrementar el efecto inmunologico.
WO2011002721A8 (en) Non-human mammal model of human hematopoietic cancer
WO2012145535A3 (en) Animal model of human cancer and methods of use
SG171674A1 (en) Methods of treating cancer by administering human il-18 combinations
MX2014008410A (es) Metodo para tratar cancer de mama.
MX348412B (es) Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.
MX359125B (es) Método para fabricar una composición que comprende un anestésico local, un heparinoide y un regulador de ph.
AU2016204146A1 (en) Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid
SG179069A1 (en) Cancer stem cell-targeted and drug resistant cancer therapy
WO2014052305A3 (en) Method for treating breast cancer using mitochondrial poisons that interfere with over-expressed mitochondrial proteins
MX2015008190A (es) Tretaspanina 33 es una candidata para la terapia dirigida de anticuerpos para el tratamiento de linfomas de hodgkin de linfocitos b.
MX2014013380A (es) Usos de cxcl17, un nuevo marcador de quimiocinas de enfermedad pulmonar y gastrointestinal humana.
MX353734B (es) Metodo para producir proteinas autologas.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 MAR 2017 BY CPA GLOBAL

Effective date: 20140116

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2018 BY AJ PARK

Effective date: 20170303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2019 BY CPA GLOBAL

Effective date: 20180726

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2020 BY CPA GLOBAL

Effective date: 20190228

LAPS Patent lapsed